Abstract：Objective: To discuss the effects of vindesine and conventional dose glucocorticoid on patients with immune thrombocytopenic purpura. Methods: 50 patients with immune thrombocytopenic purpura were divided into the observation group (n=25) and the control group(n=25), the control group were treated with conventional dose glucocorticoid, the observation group were treated with vindesine and conventional dose glucocorticoid. And the effective rate, PLT levels before and 4 weeks after the treatment, adverse reaction were contrasted between the two groups. Results: The effective rate was 75.0% in the observation group, significantly higher than 48.0% in the control group (P<0.05). PLT was significantly higher 4 weeks after the treatment than before (P<0.05); the PLT in the observation group was significantly higher in the observation group than the control group4 weeks after treatment (P<0.05). There was no significant difference in the adverse reactions between the two groups (P>0.05). Conclusion: Vindesine and conventional dose glucocorticoid has exactly effects in the treatment of patients with immune thrombocytopenic purpura. And it can increase the level of PLT, some patients can achieve long-term remission, and without serious adverse reactions, and the security is high.
邓黎黎. 长春地辛联合常规剂量糖皮质激素治疗免疫性血小板减少性紫癜的疗效观察[J]. 河北医学, 2018, 24(9): 1554-1556.
DENG Lili. Observation of the Clinical Effects of Vindesine and Conventional Dose Glucocorticoid on Patients with Immune Thrombocytopenic Purpura. HeBei Med, 2018, 24(9): 1554-1556.
[1] 金阿荣.小剂量美罗华联合地塞米松治疗难治性特发性血小板减少性紫癜11例[J].海南医学,2013,24(20):3053~3054. [2] 肖小兵.亚剂量丙种球蛋白治疗特发性血小板减少性紫癜40例临床疗效观察[J].海南医学,2013,24(5):683~684. [3] 侯明.我如何治疗糖皮质激素无效或复发的成人原发免疫性血小板减少症[J].中华血液学杂志,2017,38(5):375~378. [4] 孙彩虹,杜锋蔚,张仪.以神经症状为突出表现的血栓性血小板减少性紫癜临床分析[J].中华急诊医学杂志,2017,26(7):822~823. [5] Kikuchi K, Miyakawa Y, Ikeda S,et al. Cost-effectiveness of adding rituximab to splenectomy and romiplostim for treating steroid resistant idiopathic thrombocy topenic purpura in adults[J].BMC Health Serv Res,2015,22:15~16. [6] 林晓,王志华.妊娠合并遗传性血栓性血小板减少性紫癜治疗经验[J].中华医学杂志,2016,96(17):1386~1387. [7] Brice Fresneau, Arnaud Petit, Mary-France Courcoux,et al. Vinblas tine in the treatment of children and adolescents with refractory im- mune thrombocytopenia[J]. AM Hematol, 2011,86:785~787. [8] 何志旭,金姣.儿童常见非特发性血小板减少性紫癜[J].临床儿科杂志,2013,31(5):401~404. [9] Zhou H, Yang J, Liu L,et al.The polymorphisms of tumor necrosis factor-induced protein 3 gene may contribute to the susceptibility of chronic primary immune thrombocytopenia in Chinese population[J]. Platelets,2015,25:1~6. [10] 朱芸.特发性血小板减少性紫癜30例回顾性分析[J].影响研究与医学应用,2017,1(11):182~183. [11] Sikorska A, Slomkowski M, Marlanka K,et al. The use of vinca alka- loids in adult patients with refractory chronic idiopathic thrombocy topenia[J].Clin Lab Haematol, 2004,26:407~411. [12] 陈晓文.甘露聚糖肽口服液治疗血小板减少性紫癜的疗效观察[J].中国医药指南,2014,34(2):245~246.
2018, Vol. 24 
冀公网安备13080202000677号